Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Gynecology

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 12 articles: HTML format

Single Articles

May 2025
1. HUIS IN 'T VELD EA, Van Assche IA, Van Calsteren K, Salaets T, et al
   LONG-TERM DEVELOPMENT OF 12- AND 15-YEAR-OLD OFFSPRING AFTER MATERNAL CANCER DIAGNOSIS DURING PREGNANCY: A PROSPECTIVE MULTICENTRE COHORT STUDY.
   Ann Oncol. 2025 May 6:S0923-7534(25)00171-1. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   March 2025
2. CHAMBERS LM, Eskander RN, O'Malley DM
   Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era.
   Ann Oncol. 2025;36:244-246.
   PubMed    
   
   
   November 2024
3. SECORD AA, Lewin SN, Murphy CG, Cecere SC, et al
   The Efficacy and Safety of Mirvetuximab Soravtansine in FRalpha-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial.
   Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   
4. HARTER P, Marth C, Mouret-Reynier MA, Cropet C, et al
   Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
   Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   
5. LORUSSO D, Fuca G
   KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer?
   Ann Oncol. 2024;35:925-927.
   PubMed    
   
   
   October 2024
6. LORUSSO D, Colombo N, Dubot C, Caceres MV, et al
   Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study.
   Ann Oncol. 2024 Oct 9:S0923-7534(24)04033-X. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   September 2024
7. MONK BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, et al
   Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
   Ann Oncol. 2024 Sep 14:S0923-7534(24)03762-1. doi: 10.1016/j.annonc.2024.08.2241
   PubMed     Abstract available
   
   
   August 2024
8. VAN GORP T, Cibula D, Lv W, Backes F, et al
   ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer.
   Ann Oncol. 2024 Aug 23:S0923-7534(24)03822-5. doi: 10.1016/j.annonc.2024.08.2242
   PubMed     Abstract available
   
   
   
9. COLOMBO N, Caruso G, Jalving M
   Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story.
   Ann Oncol. 2024;35:686-688.
   PubMed    
   
   
   June 2024
10. POWELL MA, Bjorge L, Willmott L, Novak Z, et al
    Overall Survival in Patients with Endometrial Cancer Treated with Dostarlimab plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial.
    Ann Oncol. 2024 Jun 10:S0923-7534(24)00721-X. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    May 2024
11. PIGNATA S, Califano D, Lorusso D, Arenare L, et al
    MITO END-3: Efficacy of Avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
    Ann Oncol. 2024 May 2:S0923-7534(24)00128-5. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    February 2024
12. BOGANI G, Monk BJ, Powell MA, Westin SN, et al
    Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
    Ann Oncol. 2024 Feb 29:S0923-7534(24)00056-5. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.